Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results?

Cencora is set to report Q3 fiscal 2025 results on August 6th, with consensus estimates projecting revenues of $80.33 billion (+8.2% YoY) and EPS of $3.78 (+13.2% YoY). Growth is primarily driven by the U.S. Healthcare Solutions segment, fueled by strong demand for specialty medicines and GLP-1 therapies, though GLP-1 revenue saw a 10% sequential decline due to seasonal factors. This robust domestic performance is expected to largely counterbalance ongoing weakness in the International Healthcare Solutions segment, which has a lowered outlook due to soft clinical logistics and consulting demand. The integration of Retina Consultants of America (RCA) is also anticipated to positively impact Cencora's margin profile. Despite a history of earnings beats, the Zacks model does not predict an earnings beat for this quarter, although it maintains a Zacks Rank #2 (Buy).

Analysis

Cencora's upcoming third-quarter fiscal 2025 results present a bifurcated outlook, with robust domestic performance expected to contend with significant international headwinds. The consensus estimates project strong top-line and bottom-line growth, with revenue forecast at $80.33 billion (+8.2% YoY) and EPS at $3.78 (+13.2% YoY), largely propelled by the U.S. Healthcare Solutions segment. This segment's momentum is fueled by high demand for specialty medicines, including a 36% year-over-year increase in GLP-1 revenues, and a 23% rise in operating income in the prior quarter. However, a 10% sequential decline in GLP-1 revenue due to seasonal factors introduces a note of caution regarding its growth trajectory. This strength is starkly contrasted by the International Healthcare Solutions segment, which saw operating income fall 17% last quarter and faces a lowered full-year outlook due to persistent weakness in clinical trial logistics and consulting. While the recent acquisition of Retina Consultants of America (RCA) is anticipated to positively impact margins, the company's strong track record of earnings surprises (averaging a 6% beat over four quarters) is challenged by a quantitative model from Zacks that predicts no beat this time, citing a 0.00% Earnings ESP.

Key Decisions for Investors

• Investors should closely scrutinize the performance of the U.S. Healthcare Solutions segment to see if its growth can sufficiently offset the pronounced weakness and lowered outlook from the International segment.
• Pay close attention to management's commentary on GLP-1 therapy demand and seasonality to gauge the sustainability of this key growth driver, especially following its 10% sequential revenue decline last quarter.
• Given the model's prediction of no earnings beat (0.00% ESP) despite a history of positive surprises, it may be prudent to exercise caution, as the stock may not experience its typical post-earnings lift if it only meets, rather than exceeds, expectations.
• Monitor the contribution of the newly acquired Retina Consultants of America (RCA) to operating margins, as this could provide a crucial boost to profitability and signal the success of Cencora's strategy to expand in higher-margin medical services.